Analysts have been eager to weigh in on the Healthcare sector with new ratings on Certara (CERT – Research Report), Exact Sciences (EXAS – Research Report) and AbCellera Biologics (ABCL – Research Report).
Certara (CERT)
Leerink Partners analyst Michael Cherny reiterated a Hold rating on Certara on May 8 and set a price target of $19.00. The company’s shares closed last Thursday at $17.06.
According to TipRanks.com, Cherny is a 4-star analyst with an average return of
Currently, the analyst consensus on Certara is a Hold with an average price target of $19.08, a 16.9% upside from current levels. In a report issued on May 7, Robert W. Baird also maintained a Hold rating on the stock with a $19.00 price target.
See today’s best-performing stocks on TipRanks >>
Exact Sciences (EXAS)
In a report issued on May 8, Catherine Ramsey Schulte from Robert W. Baird maintained a Buy rating on Exact Sciences, with a price target of $84.00. The company’s shares closed last Thursday at $54.15.
According to TipRanks.com, Schulte is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Exact Sciences with a $88.08 average price target, representing a 61.6% upside. In a report issued on May 6, Leerink Partners also maintained a Buy rating on the stock with a $242.00 price target.
AbCellera Biologics (ABCL)
In a report issued on May 7, Puneet Souda from Leerink Partners reiterated a Buy rating on AbCellera Biologics, with a price target of $10.00. The company’s shares closed last Thursday at $3.95, close to its 52-week low of $3.62.
According to TipRanks.com, Souda is ranked 0 out of 5 stars with an average return of
AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $12.50, which is a 223.8% upside from current levels. In a report issued on May 8, KeyBanc also maintained a Buy rating on the stock with a $7.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CERT:
- Certara backs FY24 adjusted EPS view 41c-46c, consensus 43c
- Certara reports Q1 adjusted EPS 10c, consensus 10c
- Certara announces the launch of Certara Cloud
- Certara upgraded to Overweight from Sector Weight at KeyBanc
- Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
